Viewing Study NCT00301405


Ignite Creation Date: 2025-12-25 @ 3:09 AM
Ignite Modification Date: 2025-12-26 @ 1:48 AM
Study NCT ID: NCT00301405
Status: TERMINATED
Last Update Posted: 2013-08-05
First Post: 2006-03-09
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Open-Label Study of Thalidomide for Chronic Prostatitis/Chronic Pelvic Pain
Sponsor: Kenneth Peters, MD
Organization:

Study Overview

Official Title: Open-Label Study of Thalidomide for Chronic Prostatitis/Chronic Pelvic Pain
Status: TERMINATED
Status Verified Date: 2013-08
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Study closed. Difficult enrollment of patients with prostatitis.
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: To determine the efficacy of thalidomide for treatment of the Chronic Pelvic Pain Syndrome (CPPS).
Detailed Description: Prostatitis is the most common urologic diagnosis in men under the age of 50 and the third most common diagnosis in older men. In Chronic Prostatitis (CP) or Chronic Pelvic Pain Syndrome (CPPS), men have lower urinary tract symptoms, pelvic pain, sexual dysfunction and decreased quality of life. Little is known about the cause of CP/CPPS and no definitive therapy exists.

Thalidomide is an immunomodulator (a drug that alters the immune system) and it may also interfere with the development of tiny blood vessels that help support tumor growth. Therefore, in theory, it may reduce or prevent the growth of cancer cells. Thalidomide is approved by the Food and Drug Administration (FDA) for a leprosy skin condition, but not for the treatment of CP or CPPS.

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: